Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-217 (Zuranolone) for Severe Postpartum Depression
2020-001424-34Phase 3Unknown
- Sponsor
- Sage Therapeutics
- Start
- Aug 2020
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postpartum depression (PPD) comparing Zuranolone with Placebo (2 arms). Primary endpoint: Primary: Change from baseline in HAM-D total score. Status: unknown.
02
Drugs
zuranolone
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on 2020-001424-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001424-34.